CGM Use in Non-insulin Patients With DM2

Launched by MILWAUKEE VA MEDICAL CENTER · Aug 12, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether using a Continuous Glucose Monitor (CGM) helps veterans with type 2 diabetes who do not take insulin better manage their blood sugar compared to the usual fingerstick blood sugar checks. A CGM is a small device worn on the body that measures blood sugar levels continuously throughout the day, giving more detailed information than fingerstick tests. The study aims to see if using a CGM can lead to better blood sugar control, healthier eating, more physical activity, and weight loss over about a year while participating in a special diabetes support program.

Veterans who have type 2 diabetes with blood sugar levels higher than recommended (measured by a test called HbA1c between 8.0% and 12.0%) and who are not using insulin may be eligible. Participants need to be ready to start the support program and able to wear the CGM device. During the study, people will be randomly assigned to either use the CGM or continue with fingerstick testing while receiving help to manage their diabetes. This study is important because most veterans with type 2 diabetes do not use insulin, and it will help determine if CGMs are helpful for them, given that these devices can be more costly and require wearing a sensor on the body.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Successfully enrolled and ready to begin the VDOP program not on insulin therapy
• • Type 2 diabetes by clinical history
• • HbA1C between 8.0-12.0% inclusive within 3 months of enrollment
• • Assessment by clinician that patient is willing to and able to wear a CGM device
• • Stable diabetes medication regimen during the 3 months prior to entry
• Exclusion Criteria:
• • Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy
• • Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study
• • Patients with end stage renal disease (ESRD) on dialysis
• • Anticipated acute uses of glucocorticoids (oral, injectable, or IV)
• • Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration
• • Known or suspected significant allergy to use the Dexcom sensors
• • Planning or currently enrolled on different weight program different from MOVE!
• • Participating other clinical trials